Global Antimicrobial Susceptibility Test Market

Antimicrobial Susceptibility Test Market Summary, Size & Emerging Trends

According to Decision Advisor, The Global Antimicrobial Susceptibility Test Market Size is Expected to Grow from USD 3.52 Billion in 2024 to USD 8.12 Billion by 2035, at a CAGR of 7.89% during the forecast period 2025-2035. The increasing prevalence of antimicrobial resistance and the growing need for effective treatment guidance are key driving factors for the antimicrobial susceptibility test market.

Key Market Insights

• North America is expected to account for the largest share in the antimicrobial susceptibility test market during the forecast period.
• In terms of method type, the phenotypic testing segment dominated in terms of revenue during the forecast period.
• In terms of product type, the kits & reagents segment accounted for the largest revenue share in the global antimicrobial susceptibility test market during the forecast period.

Global Market Forecast and Revenue Outlook

• 2024 Market Size: USD 3.52 Billion
• 2035 Projected Market Size: USD 8.12 Billion
• CAGR (2025-2035): 7.89%
• North America: Largest market in 2024
• Asia Pacific: Fastest growing market

Antimicrobial Susceptibility Test Market

The antimicrobial susceptibility test market revolves around diagnostics that determine the effectiveness of specific antimicrobial agents against pathogens. These tests guide clinicians in selecting appropriate treatments, helping to combat rising antimicrobial resistance. The market includes phenotypic and genotypic methods, rapid diagnostics, instruments, consumables, and software tools for interpretation. Increasing hospital-acquired infections, global health awareness, and the expansion of diagnostic laboratories are fueling market growth. Governments worldwide are supporting antimicrobial stewardship programs and investing in research to combat resistance. The market is positioned for growth as healthcare systems prioritize early detection, targeted therapies, and laboratory automation.

Antimicrobial Susceptibility Test Market Trends

• The demand for rapid testing technologies is increasing, reducing turnaround times in clinical settings.
• Automation and software integration are enhancing lab efficiency and result accuracy.
• Molecular-based genotypic testing is gaining traction for its ability to detect resistance genes directly.
• Diagnostic companies are expanding product lines to offer broader testing panels and improve accessibility across regions.

Antimicrobial Susceptibility Test Market Dynamics

Driving Factors: Rising global antimicrobial resistance and demand for accurate diagnostics

Key growth factors for the antimicrobial susceptibility test market include rising antimicrobial resistance worldwide, which is creating an urgent demand for effective diagnostic solutions. The increasing number of infectious disease cases and hospital-acquired infections is pushing healthcare systems to adopt AST for targeted therapies. Technological advancements, including rapid and automated platforms, are making testing more accessible and efficient. Government initiatives, regulatory support, and funding for antimicrobial resistance monitoring programs are further accelerating adoption across clinical and research settings.

Restrain Factors: High cost of advanced testing systems and limited infrastructure in developing regions

Restraining factors in the antimicrobial susceptibility test market include the high cost of automated testing systems and consumables, especially in low-income regions. Limited access to skilled professionals and advanced laboratory infrastructure slows down adoption in underdeveloped areas. Variability in regulatory standards and test interpretations also poses challenges to global standardization. Additionally, integration challenges with hospital information systems can create barriers to full-scale implementation.

Opportunity: Expansion into emerging markets and integration of next-gen molecular platforms

The antimicrobial susceptibility test market presents numerous opportunities, particularly in emerging economies where healthcare infrastructure is rapidly developing. As awareness of antimicrobial resistance spreads, investments in diagnostic laboratories are increasing. The development of compact, automated, and rapid molecular AST platforms is creating new possibilities for point-of-care and decentralized testing. There is significant potential for strategic collaborations between diagnostic firms and healthcare providers to expand access and capabilities in underserved markets. Additionally, pharmaceutical companies are increasingly utilizing AST during drug development and surveillance activities, opening new revenue streams.

Challenges: Regulatory complexities and unequal access to diagnostic solutions

Challenges in the antimicrobial susceptibility test market include regulatory hurdles that delay product approvals and market entry. Unequal access to testing technologies across countries and regions affects the pace of global adoption. The need for high-quality reagents and standardized methodologies remains a barrier in some markets. Supply chain disruptions and dependence on global reagent suppliers can impact test availability. Furthermore, interpreting complex test results requires trained personnel, which remains a challenge in regions with a shortage of skilled healthcare workers.

Global Antimicrobial Susceptibility Test Market Ecosystem Analysis

The global antimicrobial susceptibility test market ecosystem consists of diagnostics manufacturers, reagent suppliers, software solution providers, laboratories, and healthcare institutions. Manufacturers focus on developing high-throughput, automated systems and comprehensive test kits. Reagent suppliers play a critical role in ensuring consistent test performance. Software providers support result interpretation, reporting, and data analytics. Healthcare institutions and diagnostic laboratories are the primary end-users, supported by academic and research organizations. Regulatory authorities oversee standardization, quality control, and compliance. The entire ecosystem is driven by the need for timely and accurate diagnosis, continuous innovation, and alignment with global public health priorities.

Global Antimicrobial Susceptibility Test Market, By Method Type

What factors enabled the phenotypic testing segment to lead the antimicrobial susceptibility test market in terms of revenue during the forecast period?

The phenotypic testing segment dominated the antimicrobial susceptibility test market in terms of revenue during the forecast period due to its widespread clinical adoption, cost-effectiveness, and reliability in detecting antimicrobial resistance. Phenotypic methods provide direct observation of bacterial growth inhibition in the presence of antibiotics, making them a trusted choice for healthcare providers worldwide. Additionally, advancements in automation and standardization of phenotypic testing have enhanced turnaround times and accuracy, further solidifying its competitive edge. The segment’s ability to accommodate a broad spectrum of pathogens and its integration into routine diagnostic workflows contributed significantly to its market leadership.

Why is the genotypic testing segment anticipated to experience the fastest growth in the market?

The genotypic testing segment is expected to grow at the fastest rate due to its ability to provide rapid, highly sensitive, and specific detection of antimicrobial resistance genes. Unlike traditional phenotypic methods, genotypic tests can identify resistance mechanisms at the molecular level, enabling quicker decision-making and targeted therapy. Advances in molecular technologies such as PCR, next-generation sequencing, and microarrays have made genotypic testing more accessible and affordable. Additionally, increasing awareness of antibiotic resistance and the need for precise diagnostics in clinical and research settings are driving demand. The segment’s efficiency, accuracy, and potential to reduce treatment delays are key advantages fueling its accelerated growth in the market.

Global Antimicrobial Susceptibility Test Market, By Product Type

How did the kits & reagents segment gain a competitive edge in the antimicrobial susceptibility test market during the forecast period?

The kits & reagents segment accounted for the largest revenue share in the global antimicrobial susceptibility test market during the forecast period due to its essential role in ensuring the accuracy, reliability, and standardization of test results. These kits and reagents are critical components in both phenotypic and genotypic testing methods, driving consistent performance across laboratories worldwide. The segment benefited from continuous innovation, increased availability, and compatibility with automated testing platforms, which enhanced efficiency and throughput. Additionally, strong demand from clinical, pharmaceutical, and research sectors for high-quality and ready-to-use kits supported sustained revenue growth. The convenience, precision, and broad applicability of kits & reagents made this segment the preferred choice, enabling it to dominate market revenue during the forecast period.

What makes the software & services segment increasingly attractive in the antimicrobial susceptibility test market?

The software & services segment is experiencing growing interest in the antimicrobial susceptibility test market due to the increasing need for advanced data management, interpretation, and integration capabilities. As antimicrobial testing generates vast amounts of complex data, software solutions offer streamlined analysis, enhanced accuracy, and faster reporting, which are critical for timely clinical decisions. Additionally, services such as training, technical support, and consulting are helping laboratories optimize test workflows and maintain compliance with regulatory standards. The rise of automation and digital health initiatives further propel demand for these solutions.

North America is expected to account for the largest share of the antimicrobial susceptibility test market during the forecast period, holding approximately 40% of the global market revenue.

  The region’s dominance is primarily driven by its advanced healthcare infrastructure, significant investments in research and development, and a strong emphasis on antimicrobial stewardship programs. Furthermore, the presence of leading diagnostic companies and prominent academic research institutions in North America continues to strengthen the market’s position by fostering innovation and expanding the availability of antimicrobial susceptibility testing.

The United States plays a pivotal role within this region,

with a large number of clinical laboratories, ongoing public health initiatives to combat antibiotic resistance, and substantial funding for healthcare and diagnostics. The growth of the U.S. market is further propelled by the rising prevalence of infectious diseases and the expanding demand for rapid and accurate antimicrobial testing methods in hospitals and diagnostic centers.

 

In contrast, the Asia Pacific region is projected to witness the fastest CAGR of approximately 8.5% during the forecast period.

The region’s rapid expansion is fueled by continuous improvements in healthcare infrastructure and growing awareness about antimicrobial resistance in countries such as India, China, and Japan. Increasing diagnostic capabilities and the expansion of clinical laboratories are further contributing to market growth. Additionally, government initiatives aimed at strengthening laboratory networks and enhancing disease surveillance systems support this upward trend.

India is experiencing significant growth in the antimicrobial susceptibility test market,

due to its expanding healthcare sector and rising investments in diagnostic technologies. The country’s large population and increasing incidence of infectious diseases create substantial demand for efficient antimicrobial testing. Government programs focused on tackling antimicrobial resistance and improving healthcare access are also critical drivers, positioning India as a key growth market within the Asia Pacific region.

WORLDWIDE TOP KEY PLAYERS IN THE ANTIMICROBIAL SUSCEPTIBILITY TEST MARKET INCLUDE

• bioMérieux
• Becton, Dickinson and Company (BD)
• Thermo Fisher Scientific Inc.
• Danaher Corporation
• Bio-Rad Laboratories
• Merck KGaA
• Roche Diagnostics
• HiMedia Laboratories
• Liofilchem S.r.l.
• Accelerate Diagnostics Inc.
• Others

Product Launches in Antimicrobial Susceptibility Test Market

• In June 2023, Sysmex Corporation launched the PA-100 AST System in Europe, marking a significant advancement in point-of-care diagnostics. Utilizing proprietary microfluidic technology, this system delivers antimicrobial susceptibility test (AST) results directly from urine samples within just 30 minutes. Designed for use in primary care settings, it enables healthcare professionals to determine the effectiveness of antimicrobials promptly, promoting appropriate usage and contributing to the fight against antimicrobial resistance (AMR).

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decision Advisor has segmented the antimicrobial susceptibility test market based on the below-mentioned segments: 

Global Antimicrobial Susceptibility Test Market, By Method Type

• Phenotypic Testing
• Genotypic Testing
• Rapid Testing

Global Antimicrobial Susceptibility Test Market, By Product Type

• Instruments
• Kits & Reagents
• Software & Services

Global Antimicrobial Susceptibility Test Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

FAQs

Q: Which method type segment dominates the Antimicrobial Susceptibility Test Market in terms of revenue?
A: The phenotypic testing segment dominated the market in terms of revenue during the forecast period.

Q: Which method type segment is expected to grow the fastest in the Antimicrobial Susceptibility Test Market?
A: The genotypic testing segment is anticipated to experience the fastest growth due to rapid and sensitive detection of resistance genes.

Q: Which product type segment accounted for the largest revenue share in the Antimicrobial Susceptibility Test Market?
A: The kits & reagents segment accounted for the largest revenue share during the forecast period.

Q: What makes the software & services segment increasingly attractive in the Antimicrobial Susceptibility Test Market?
A: Software & services are growing due to the increasing need for advanced data management, interpretation, faster reporting, and lab workflow optimization.

Q: Who are the top key players operating in the Global Antimicrobial Susceptibility Test Market?
A: Leading players include bioMérieux, Becton, Dickinson and Company (BD), Thermo Fisher Scientific Inc., Danaher Corporation, Bio-Rad Laboratories, Merck KGaA, Roche Diagnostics, HiMedia Laboratories, Liofilchem S.r.l., and Accelerate Diagnostics Inc.

Q: What are the main drivers of growth in the Antimicrobial Susceptibility Test Market?
A: Rising antimicrobial resistance, increasing prevalence of infectious diseases, demand for accurate diagnostics, technological advancements, and government initiatives on antimicrobial stewardship are key growth drivers.

Q: What challenges are limiting the adoption of Antimicrobial Susceptibility Test products?
A: High costs of advanced testing systems, limited infrastructure in developing regions, regulatory complexities, and shortage of skilled professionals are major restraints.

Q: Which application or end-use segment is expected to grow the fastest over the next 10 years?
A: Clinical diagnostic laboratories and healthcare institutions are expected to drive the fastest growth, supported by expanding diagnostic capabilities and hospital infection control programs.

Q: How do North America and Asia Pacific compare in terms of market growth?
A: North America holds the largest market share due to advanced healthcare infrastructure, while Asia Pacific is the fastest-growing region driven by healthcare improvements and rising awareness.

Q: What are the latest trends in the Antimicrobial Susceptibility Test Market?
A: Increasing demand for rapid testing technologies, automation, molecular genotypic testing, and software integration are key emerging trends.

Q: What are the top investment opportunities in the Global Antimicrobial Susceptibility Test Market?
A: Investments in next-generation molecular platforms, rapid point-of-care diagnostics, expansion into emerging markets, and digital health solutions offer attractive opportunities.

Q: What is the long-term outlook (2025–2035) for the Antimicrobial Susceptibility Test Market?
A: The market is expected to sustain strong growth due to rising antimicrobial resistance, healthcare system prioritization of early detection, and expansion in clinical and research diagnostics.